first-line osimertinib in egfr mutant ansclc patients: progression pattern and safety in the rea...
Published 3 years ago • 165 plays • Length 5:26Download video MP4
Download video MP3
Similar videos
-
1:36
comment: front-line osimertinib significantly lengthens overall survival in egfr-mutation positi...
-
3:31
osimertinib plus gefitinib for treatment of egfr-mutated non-small cell lung cancer
-
2:21
osimertinib ipilimumab in egfr-mutated nsclc
-
6:56
first-line therapy in the patient with egfr-mutant lung cancer
-
6:28
sequential treatment with afatinib and osimertinib in patients with egfr mutation-positive nsclc
-
3:20
egfr mutated nsclc disease progression on osimertinib - 2022 program: targeted therapies forum
-
6:43
sequential afatinib and osimertinib in egfr mutation-positive nsclc patients: updated results
-
8:44
flaura final analysis: osimertinib for first-line egfrm nsclc
-
5:06
front-line osimertinib significantly lengthens overall survival in egfr-mutation positive nsclc
-
9:54
amivantamab combo with lazertinib favourable in post-osimertinib egfr-mutant nsclc
-
2:14
dr. yang on osimertinib as first-line therapy for egfr-positive nsclc
-
3:31
osimertinib suitable for first line egfrm lung cancer
-
11:47
osimertinib as first-line treatment for egfr mutation-positive advanced nsclc? (bmic-017)
-
4:51
early returns on flaura trial: osimertinib as first line agent in egfr mut-pos. nsclc? (bmic-002)
-
6:06
osimertinib, the standard for egfr nsclc
-
16:45
amivantamab in combination with lazertinib for osimertinib-relapsed, chemo-naïve egfrm nsclc
-
9:02
amivantamab plus lazertinib for egfr-mutant lung cancer following progression on osimertinib
-
2:03
amivantamab and lazertinib in treatment-naïve egfr-mutant nsclc
-
3:30
osimertinib for uncommon egfr mutations in nsclc